Faron Pharmaceuticals Oy (FARN.L)
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Company Info
Highlights
£186.38M
-£0.32
-£16.70K
£85.00 - £290.00
£996.78
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in Faron Pharmaceuticals Oy, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Faron Pharmaceuticals Oy had a return of -18.29% year-to-date (YTD) and -36.79% in the last 12 months.
FARN.L
-18.29%
-20.24%
-4.29%
-36.79%
-9.77%
N/A
^GSPC (Benchmark)
3.96%
1.97%
9.03%
22.16%
12.60%
11.26%
Monthly Returns
The table below presents the monthly returns of FARN.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -15.85% | -18.29% | |||||||||||
| 2024 | -4.92% | -56.03% | 7.84% | 5.45% | 27.59% | -46.76% | 73.10% | 20.23% | 11.22% | -27.63% | 3.03% | 20.59% | -32.79% |
| 2023 | -1.67% | 10.17% | -6.15% | 4.59% | -14.42% | -10.99% | 16.46% | 9.54% | 0.00% | -17.74% | 1.96% | 17.31% | 1.67% |
| 2022 | -8.62% | 0.40% | -10.20% | 4.68% | -3.19% | -5.49% | -5.81% | -12.35% | 4.23% | -8.11% | 75.00% | 0.84% | 10.09% |
| 2021 | 61.54% | -22.02% | 2.29% | -1.49% | 12.88% | 1.34% | 11.26% | 0.60% | -11.24% | -9.33% | -8.82% | -12.10% | 4.81% |
| 2020 | -10.48% | 39.36% | 43.51% | -19.68% | -7.28% | -2.86% | 13.24% | 23.38% | -11.58% | -30.95% | -5.17% | -5.45% | -0.95% |
| 2019 | 11.71% | 1.61% | -3.17% | -3.28% | 75.42% | 5.80% | 7.31% | -10.62% | -5.24% | 79.40% | 44.26% | 1.94% | 373.07% |
| 2018 | 4.38% | 5.69% | -6.80% | -0.30% | -84.21% | -45.17% | 8.45% | 40.91% | -5.07% | -27.18% | -22.00% | -5.13% | -93.06% |
| 2017 | 20.75% | 10.94% | 57.75% | 28.57% | 7.99% | -5.14% | -4.75% | -0.36% | 18.21% | 0.91% | 1.80% | -5.88% | 201.89% |
| 2016 | 4.08% | 2.94% | 0.00% | -1.90% | 0.00% | -4.85% | 1.02% | 1.01% | 2.00% | 0.00% | 0.00% | 3.92% | 8.16% |
| 2015 | 2.70% | -14.04% | -11.71% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of FARN.L is 47, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Faron Pharmaceuticals Oy (FARN.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Faron Pharmaceuticals Oy. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Faron Pharmaceuticals Oy was 94.05%, occurring on Jan 22, 2019. The portfolio has not yet recovered.
The current Faron Pharmaceuticals Oy drawdown is 81.02%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.05% | Mar 2, 2018 | 225 | Jan 22, 2019 | — | — | — |
| -22.22% | May 8, 2017 | 1 | May 8, 2017 | 90 | Sep 13, 2017 | 91 |
| -14.91% | Dec 2, 2015 | 24 | Jan 7, 2016 | 264 | Jan 24, 2017 | 288 |
| -12.41% | Apr 7, 2017 | 3 | Apr 11, 2017 | 9 | Apr 26, 2017 | 12 |
| -11.14% | Sep 15, 2017 | 65 | Dec 15, 2017 | 45 | Feb 21, 2018 | 110 |
Volatility
Volatility Chart
The current Faron Pharmaceuticals Oy volatility is 19.03%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Faron Pharmaceuticals Oy.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |